Generation of Aspergillus- and CMV-specific T-cell responses using autologous fast DC

Cytotherapy

Volumn 6, Issue 3, 2004, Pages 223-234

  Ramdan, G ^a   Konings, S ^a   Kurup, V P ^b   Keever Taylor, C A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aspergillus fumigatus; CMV; CTL; Fast DC; Mo derived DC

Indexed keywords

CD14 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CELL SURFACE MARKER; CYTOKINE; CYTOMEGALOVIRUS ANTIGEN PP65; FUNGUS ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; ASPERGILLUS FUMIGATUS; AUTOGRAFT; CELL ACTIVITY; CELL ADHESION; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL KILLING; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; COST CONTROL; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MEDICAL ASSESSMENT; MONOCYTE; PHENOTYPE; T LYMPHOCYTE; TIME; WORKLOAD;

EID: 3042725540     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240410006040     Document Type: Article

References (56)

1. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
2. Dieu MC, Vanbervliet B, Vicari A et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188:373-86.
3. Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000;177:134-40.
4. Randolph GJ, Beaulieu S, Lebecque S et al. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 1998;282:480-3.
5. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10-6.
6. Cella M, Scheidegger D, Palmer-Lehmann K et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-52.
7. Schnurr M, Then F, Galambos P et al. Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. J Immunol 2000;165:4704-9.
8. de Jong EC, Vieira PL, Kalinski P et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol 2002;168:1704-9.
9. + leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol 1996;59:208-18.
10. + dendritic cells. Proc Natl Acad Sci USA 1996;93:2588-92.
11. + cells. Br J Haematol 1998;101:756-65.
12. + haematopoietic progenitors by PMA and in serum-free medium. Clin Exp Immunol 2001;125:237-44.
13. Molldrem JJ. Antigen-specific lymphocyte therapies. Cytotherapy 2002;4:315-6.
14. Kochenderfer JN, Molldrem JJ. Leukemia vaccines. Curr Oncol Rep 2001;3:193-200.
15. + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003;171:2251-61.
16. Bender A, Sapp M, Schuler G et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996;196:121-35.
17. Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-42.
18. Thurner B, Roder C, Dieckmann D et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
19. Ho CS, Munster D, Pyke CM et al. Spontaneous generation and survival of blood dendritic cells in mononuclear cell culture without exogenous cytokines. Blood 2002;99:2897-904.
20. Dauer M, Obermaier B, Herten J et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 2003;170:4069-76.
21. Kurup VP, Xia JQ, Rickaby DA et al. Aspergillus fumigatus antigen exposure results in pulmonary airway resistance in wild-type but not in IL-4 knockout mice. Clin Immunol 1999;90:404-10.
22. Keever-Taylor CA, Margolis D, Konings S et al. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. Biol Blood Marrow Transplant 2001;7:247-56.
23. Emtage PC, Clarke D, Gonzalo-Dagonzo R et al. Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity. J Immunother 2003;26:97-106.
24. Palucka KA, Taquet N, Sanchez-Chapuis F et al. Dendritic cells as the terminal stage of monocyte differentiation. J Immunol 1998;160:4587-95.
25. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18.
26. LIgMM transgene expression in DC via a GPI-anchor using a novel retroviral vector induces an in vitro autologous T-cell proliferation restricted to MHC class I molecules. Hematol J 2003;4:121-31.
27. Hausser G, Ludewig B, Gelderblom H et al. Monocyte-derived dendritic cells represent a transient stage of differentiation in the myeloid lineage. Immunobiology 1997;197:534-42.
28. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-803.
29. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin N Am 2002;16:875-94.
30. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003;102:827-33.
31. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.
32. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003;4:974-90.
33. Cenci E, Mencacci A, Del Sero G et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999; 180: 1957-68.
34. Romani L. The T cell response against fungal infections. Curr Opin Immunol 1997;9:484-90.
35. Grazziutti ML, Rex JH, Cowart RE et al. Aspergillus fumigatus conidia induce a Th1-type cytokine response. J Infect Dis 1997;176:1579-83.
36. Kurup VP, Shen HD, Vijay H. Immunobiology of fungal allergens. Int Arch Allergy Immunol 2002;129:181-8.
37. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-66.
38. Cenci E, Mencacci A, Bacci A et al. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000;165:381-8.
39. Bozza S, Gaziano R, Lipford GB et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 2002;4:1281-90.
40. Bozza S, Perruccio K, Montagnoli C et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003;102:3807-14.
41. Kurup VP. Fungal allergens. Curr Allergy Asthma Rep 2003;3:416-23.
42. Banerjee B, Kurup VP, Greenberger PA et al. Cloning and expression of Aspergillus fumigatus allergen Asp f 16 mediating both humoral and cell-mediated immunity in allergic bronchopulmonary aspergillosis (ABPA). Clin Exp Allergy 2001;31:761-70.
43. Borysiewicz LK, Graham S, Hickling JK et al. Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity. Eur J Immunol 1988;18:269-75.
44. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-88.
45. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993;118:179-84.
46. Boeckh M, Bowden RA, Gooley T et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999;93:1781-2.
47. Einsele H, Hebart H, Kauffmann-Schneider C et al. Risk factors for treatment failures in patients receiving PCR-based pre-emptive therapy for CMV infection. Bone Marrow Transplant 2000;25:757-63.
48. Carlsson B, Cheng WS, Totterman TH et al. Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. Br J Haematol 2003;121:428-38.
49. + cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 1994;14 Suppl 4:S78-84.
50. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-41.
51. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
52. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001;97:994-1000.
53. + T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. Blood 2002;99:213-23.
54. + cytolytic T cell responses. J Exp Med 1995;182:1663-71.
55. Brossart P, Goldrath A, Butz E et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997;158:3270-6.
56. Van Gool SW, Vermeiren J, Rafiq K et al. Blocking CD40-CD154 and CD80/CD86-CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production. Eur J Immunol 1999;29:2367-75.